Behavioural science, and the changes it can bring to patient and healthcare provider behaviour, has important implications for pharmaceutical companies and health systems alike.
Health Secretary Matt Hancock has been urged to immediately review the epilepsy medicine supply chain, after ongoing problems for patients who are struggling to obtain their treatments.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
